Our lead compound OT-003

Our lead asset OT-003, a proprietary small molecule, shows compelling results across a range of cellular and in vivo models for CNS diseases. We plan to initiate Phase 1 clinical studies with OT-003 by 2025 and we are building a pipeline of NCEs to treat a wide range of neurological and neuropsychiatric disorders.

Urgent need for new treatments addressing neurological and neuro-psychiatric diseases

By 2050 the global patient population with Central Nervous System (CNS) disorders will experience significant growth, adding to the huge unmet medical need of today.


People suffer from dementia globally


Approved disease modifying therapies for Parkinson's Disease


Of schizophrenia patients are treatment resistant


Years life expectancy after diagnosis with ALS


Our lead program OT-003 focuses on the TrkB receptor pathway


Multiple disease hallmarks underlie CNS disorders including neuronal loss, synaptic and neuronal dysfunction, pathological protein aggregation, inflammation and mitochondrial dysfunction. These processes drive progressive loss of neurons, leading to impairment in memory, cognition, behavior and motor function.


Our most advanced R&D program focuses on the TrkB receptor pathway. Impaired TrkB signaling is implicated in a range of neurological and psychiatric conditions. Activation of the TrkB receptor activates downstream signaling pathways enhancing neuronal survival, promoting neuronal and synaptic plasticity, reducing neuroinflammation and pathological protein aggregates including α-synuclein, amyloid-β and tau. In addition, TrkB activation leads to an improvement in mitochondrial function and an increase in BDNF production, the endogenous ligand for the TrkB receptor.


Our lead compound, OT-003, binds to the TrkB receptor, leading to activation of the downstream signaling pathways and promoting the above effects in both cellular and in vivo experiments. This pharmacology ultimately leads to significant improvements in memory, cognition and motor function as shown in a range of in vivo studies.


We plan to initiate Phase 1 clinical studies with OT-003 by Q1 2025 - with the PangeAI platform driving future expansion

To further complement our lead molecule, we are developing a portfolio of TrkB-activating compounds, to treat a wide range of neurological disorders with high unmet medical need, and which can have a transformative impact on patients and their families.

Inspired by nature.
Powered by technology.
Preserving knowledge.
Empowered by nature.
Empowered by nature.
Empowered by nature.
Empowered by nature.
Empowered by nature.